Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown in the SELECT Trial to be effective in preventing the loss of kidney function in people who are overweight or obese and have established cardiovascular disease but do not have diabetes
New Delhi [India], May 15: High blood pressure, a silent killer, threatens India's public health. The World Health Organization (WHO) reports that one-third of deaths in India are attributable to non-communicable diseases, with cardiovascular diseases leading the way. Hypertension is the mos
GHRD, which is defined by the body's inability to use its growth hormone and leads to stunted development, has been linked in mice to a 40 per cent increase in longevity and decreased risk of numerous age-related disorders. However, the risk of cardiovascular illness in individuals with GHRD
Researchers at Rutgers Health discovered that hypertensive problems during pregnancy are substantially related to deadly cardiovascular disease up to a year after birth.
Mumbai (Maharashtra) [India], April 10: Roche Diagnostics India announces the launch of its point-of-care NT-proBNP test for screening diabetes patients who are at risk of cardiovascular diseases (CVD) such as heart failure (HF). This breakthrough innovation is designed to bring testing clos
According to a new study, increased sedentary time beginning in childhood is related with deteriorating arterial stiffness, a surrogate for premature vascular damage. However, light physical activity may help to minimise the risk.
Speaking at 'ANI Dialogues 2024-Navigating India's Health Sector', Dr Sandeep Nayar, Prinicipal Director and HOD, Chest and Respiratory Diseases, BLK Hospital on Saturday said that lack of outdoor activities, change in lifestyle among others have contributed a lot.
Certain hypertension-related genes influence blood pressure from an early age and raise the risk of cardiovascular disease as you become older. However, there is something you can do about it.
According to new research, nearly 500 adults with obesity who took the new weight loss medication tirzepatide for about eight months saw a significant reduction in their systolic blood pressure--the top number in a blood pressure reading.
Sleep apnea, which causes periodic, brief disruptions in breathing while sleeping, can disrupt blood lipid control, a major factor in the development of cardiovascular disease. A University of Ottawa research team discovered that the effect of sleep apnea on blood lipid metabolism varies by
In patients with rheumatoid arthritis, the molecule RvT4 strengthens the body's defences against atherosclerosis, or hardening of the arteries, according to research from Queen Mary University of London